| Funding: |
Total for 1986 through 2005 = $4,913,704 |
| National Cancer Institute of Canada |
| 2002 |
$133,405/yr 3yrs. (Co-investigator with M. Hough) Title: Pathogenesis of tumor progression in a transgenic mouse model for lymphoma. |
| 1999 |
$110,639/yr 3 Years. (Principal investigator with M. Hough) Title: Pathogenesis of tumor progression in a transgenic mouse model for lymphoma. |
| 1997 |
$156,413/yr 3 Years Operating Grant (Co-investigator with A.K. Stewart, A. Abrams-Ogg and S. Kruth) Title: MDR-1 transduced autologous marrow cells for chemoprotection in metastatic breast cancer. |
| 1992 |
$121,694/yr 3 Years Operating Grant (Principal investigator with S. Kamel-Reid). Title: Characterization of HOX11: A new gene involved in human cancer. |
Canadian
Institutes for Health Research
(Medical Research Council of Canada) |
| 2001 |
$50,000/yr 5 years (Network Center of Excellence). Title: Stem Cell Genomics and Therapeutic Network . |
| 1998 |
$97,653/yr 4 years (Principal investigator with co-investigators S. Kruth and ACG Abrams - Ogg). Title: Gene therapy in a model system: Canine alpha-iduronidase deficiency. |
| 1997 |
$45,528 Operating Grant (Principal investigator with co-investigators A.K. Stewart, S. Kruth, and ACG Abrams-Ogg). Title: Gene transfer into pluripotent hematopoietic progenitor cells. |
| 1994 |
$94,000/yr 3 Years Operating Grant (Principal investigator with co-investigators S. Kamel-Reid, S. Kruth, and ACG Abrams-Ogg). Title: Gene transfer pluripotent hematopoietic progenitor cells. |
| 1993 |
$30,000/yr 1 Year Operating Grant (Principal investigator with co-investigators S. Kamel-Reid, S. Kruth, and ACG Abrams-Ogg). Title: Gene transfer into pluripotent hematopoietic progenitor cells. |
| 1990 |
$75,100/yr 3 Years Operating Grant (Principal investigator with co-investigators VEO Valli and S Kruth). Title: Canine model for autologous bone marrow transplantation using long-term bone marrow culture cells. |
| 1989 |
$57,000/yr 3 Years Operating Grant (Principal investigator). Title: Cloning and characterization of the oncogene involved in the 10;14 translocation of T-cell neoplasia. |
| 1988 |
$56,000/yr 2 Years Operating Grant (Principal investigator with co-investigators VEO Valli and S Kruth). Title: Canine model for autologous bone marrow transplantation using long-term bone marrow culture cells. |
| 1996 |
$3,600 PMAC/MRC Studentship Grant (Tara Paton) |
| 1995 |
$2,500 Symposium Grant (Gene Therapy in Canada) |
| 1995 |
$3,500 Supervisor's Grant (David Allan) |
| 1994 |
$3,500 Supervisor's Grant (David Allan) |
| 1989 |
$1,300 Supervisor's Grant (Ron Carter) |
| 1988 |
$1,300 Supervisor's Grant (Ron Carter) |
| 1987 |
$1,300 Supervisor's Grant (Ron Carter) |
| Bayer Blood Partnership Fund |
| 2000 |
$249,356 for 2 Years (Renewal application-Outcome Pending). (Principal investigator). Title: Molecular genetic characterization of the inductive hematopoietic microenvironment. |
| 1998 |
$58,000/yr 2 Years Operating Grant. (Principal investigator). Title: Molecular genetic characterization of the inductive hematopoietic microenvironment. |
| University of Toronto |
| 1987 |
$30,000 Faculty of Medicine, Excellence Award. |
| 1986 |
$5,000 Dean's Fund Award. |
| Toronto General Hospital |
| 1986 |
$13,000 Oncology Research, Start-up Fund |
| The Hospital For Sick Children Foundation |
| 1994 |
$55,000/yr 2 Years Operating Grant (Principal investigator). Title: Gene therapy for human ADA-deficiency. |
| 1990 |
$48,000/yr 2 Years Operating Grant (Principal investigator). Title: Molecular characterization of breakpoints in complex Philadelphia chromosomes. |
| 1988 |
$50,000/yr 2 Years Operating Grant (Principal investigator). Title: Molecular characterization of the (10;14) translocation of childhood T-cell acute lymphoblastic leukemia. |
| Canadian Universities Research Program - Connaught Laboratories Ltd. |
| 1994 |
$120,000/yr 3 Years Operating Grant (Principal investigator) . Title: A mouse model for human gene therapy. |
| The Banting Medical Research Foundation |
| 1988 |
$10,000 Equipment Grant. Title: Cloning and characterization of the oncogene involved in the 10;14 translocation of T-cell neoplasia. |
| Somatix Therapy Corp. |
| 1995 |
$57,876 Research Contract (Principal investigator). Title: Transduction of hematopoietic stem cells with the MFG virus carrying the human glucocerebrosidase gene. |
| Genetic Therapy Inc. |
| 1996 |
$ 83,808 Research Contract (Principal Investigator) Title: Transfer of the MDR gene into hematopoietic stem cells. |
| Baxter (US) Gene Therapy Division. |
| 1996 |
$448,500 Research Contract. (Co-investigator with K. Stewart, F. Graham, and J. Gauldie) Title: A phase II clinical trial of adenoviral mediated gene transfer of IL-2 cDNA into metastatic breast cancer and melanoma. |
| The Canadian Society for Mucopolysaccharide and Related Diseases Inc. |
| 1996 |
$5,000 (Principal investigator with S. Kruth co-investigator). Title: Support for a canine MPS 1 colony. |
| Other Corporate Research Awards |
| 1995 |
$27,350 Funding for Gene Therapy in Canada Conference. Donors include: Inex, Hemosol, Biochem, Glaxo, Genentech, Novopharm, Coopers & Lybrand, MDS Health Group, Allelix, Dalton, General Synthesis & Diagnostics Inc., Bayer, Scott & Aylen, Cansera, Eli Lilly, Toronto Biotechnology Initiative, Connaught, Imutec, Spectral Diagnostics Inc., Canadian Institute of Biotechnology, Medical Research Council. |
Top Of Page
|
